Many questions - no answersAEZS's diagnostic trial was expected to be enrolled in Q4 2023. What is the trial results are released with a licensing deal? The 5X PGX scale-up is expected to be commissioned this quarter. What if they announce the successful commissioning along with a licensing deal? That would only leave the 10X scale-up which had 50% of the equipment and infrastructure believed needed in place as of the November news release. It could be in the home stretch to the point of decision concerning mass industrialization of PGX. The 100L facility also allows for commercial production in and of itself. What if CZO also reports its avenanthramide pill data. The single ascensing dose portion of the study could be completed this month. What if the additional wound healing data is also reported. AEZS is also nearing a go decision for its AIM Biologicals program concerning clinical trials. CZO also announced in November that it had designed an trial in animals that could further substantiate CZO's immune booster. This could further support a decision to move forward an immune booster plant as PGX is further de-risked.
It is clear why the stock market does not pay money for these thousand question marks.
What if Gilles stopped paying money for Proph?
Answer: CZO would save money!